The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Background Implantable cardioverter-defibrillators (ICDs) are implanted with the intention to
prolong life in selected patients with inherited arrhythmia syndromes, but ICD implantation is …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Background The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to
avoid complications related to the transvenous ICD lead by using an entirely extrathoracic …

5.2. 1. Ocena funkcji skurczowej lewej komory...................................... 1052 5.2. 2. Ocena
funkcji rozkurczowej lewej komory...................................... 1052 5.2. 3. Ocena funkcji prawej …

Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was
developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads …

Aims The totally subcutaneous implantable-defibrillator (S-ICD) is a new alternative to the
conventional transvenous ICD system to minimize intravascular lead complications. There …

Las guías de práctica clínica (GPC) tienen como objetivo reunir y evaluar toda la evidencia
relevante disponible durante el proceso de elaboración sobre un tema particular para …

Background: Transvenous implantable cardioverter-defibrillators (TV-ICDs) improve survival
in patients at risk for sudden cardiac death, but complications remain an important …

Importance Trends and in-hospital outcomes associated with early adoption of the
subcutaneous implantable cardioverter defibrillator (S-ICD) in the United States have not …